References: 1. Rosenfeld CR, et al. Endocr Pract. 2012;18(5):660-667. 2. V-Go® Instructions for Patient Use. Valeritas, Inc. 2011. 3. Kapitza C, et al. J Diabetes Sci Technol. 2008;2(1):40-46. 4. Omer A, et al. Poster presented at: American Diabetes Association 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL. Abstract 980-P. 5. Grunberger G, et al. Poster presented at: American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress; May 14-18, 2014; Las Vegas, NV. Abstract 224. 6. Lajara R, Nikkel C. Poster presented at: American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress; May 13-17, 2015; Nashville, TN. Poster 273T.
Important Risk Information
If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.